What To Know About Jiyoutai—China's First Potential Ozempic Challenger

The new biosimilar drug could pose the first major challenge to Ozempic in China, where Novo Nordisk’s patent is set to expire in 2026.

Related Keywords

Hong Kong ,Jiuyuan ,Hunan ,China ,Chinese ,Mette Kruse Danielsen ,Eli Lilly ,China Intellectual Property Office ,Reuters ,Drug Administration ,Novo Nordisk ,Jiuyuan Gene Engineering ,Jiuyuan Gene ,Wall Street ,Intellectual Property Office ,Chinese Based Innovent ,Ozempic ,